This article is more than 2 months old

GM Kemman

April 22, 2022

Good Government Protects Inalienable Human Rights

April 21, 2022, Governor Justice announced $5.7 million dollars in Community Development Block Grant-CARES funding for "several projects that will combat COVID-19 in communities across West Virginia." The abundant flow of federal funds into states helps explain why the Governor's March 16, 2020 State-of-Emergency declaration remains in place over two years later, and why he continues to promote ineffective and toxic injections known to damage immune systems. Deaths from all causes increased in 2021, and not owing to COVID-19.

Pfizer Inc., the favored producer of the highly-touted experimental products, reported profits of $22 billion, in 2021 alone. The United States Department of Defense supported Pfizer in its COVID endeavor, including granting immunity from liability, despite Pfizer's 2009 guilty plea to the felony of "intent to defraud or mislead." For this offense, Pfizer paid a fine of $2.3 billion, "the largest health care fraud settlement in the history of the Department of Justice."

Safe and effective generic treatments for corona-virus-related illnesses had been identified long before 2020. In keeping with this knowledge, March 24, 2020, Governor Justice announced Mylan of West Virginia would be increasing production of the off-patent medicine hydroxychloroquine.

Alas, hydroxychloroquine and other safe and life-saving drugs stood in the way of DOD's Operation Warp Speed and a coveted Emergency Use Authorization for experimental genetic injections. Gaining a fast track to FDA approval took precedence over human lives.

How many died or suffered injuries because they were denied cheap and safe preventatives and treatments like hydroxychloroquine? How many suffered economic, physical, and psychological damages caused by emergency measures: closures, distancing, lockdowns, mandates, perverse financial incentives for doctors and hospitals, and travel restrictions? How many lives have been permanently harmed by the cumulative damage caused by these persistent violations of human rights?

Outspoken doctors hoping to save lives have been brutally censored by social media companies and medical journals and attacked by public officials and state medical boards. Outspoken scientists, politicians, journalists, and citizens have been similarly mistreated.

In November 2020, Pfizer's Chief Executive Officer, Albert Bourla, announced: "We are proud to have completed the combination of Upjohn and Mylan to create Viatris and pleased to have delivered value to our shareholders through this transaction." July 31, 2021, Viatris closed its West Virginia facility, leaving over 1,400 people out of work.

Billions in corporate, "charitable" foundation, and taxpayer funds have been spent on propaganda to promote deadly frauds perpetrated by the military-pharmaceutical-industrial-technocratic complex, and billions have been funneled from government treasuries to encourage well-meaning people to enable and perpetuate destructive lies.

Technocrats plan to impose totalitarianism on all of humanity through "emergencies" and binding "agreements" with organizations such as the World Health Organization and the United Nations. Using fear as a tool, they teach decent people to believe the greater good can only be achieved through control by elite managers. This belief undermines precious human liberty and the sovereignty of individuals, communities, and nations.

Good government protects inalienable human rights—all else is tyranny.

SOURCES

Office of the Governor, *Gov. Justice announces over $5.7 million in CDBG-CV grant awards for projects to combat COVID-19 across West Virginia*, GOVERNOR.WV.GOV, (April 21, 2022), (April 22, 2022, 11:19 AM), https://governor.wv.gov/News/press-releases/2022/Pages/Governor-Justice-announces-CDBG-CV-grant-awards-for-projects-to-combat-COVID-19.aspx.

Office of the Governor, *Public health disaster emergency declaration to end April 15*, GOV.IDAHO.GOV, (March 8, 2022), (April 22, 2022, 11:23 AM), https://gov.idaho.gov/pressrelease/public-health-disaster-emergency-declaration-to-end-april-15/.
"The activation of a statewide public health emergency since the start of the pandemic has enabled the Federal Emergency Management Agency (FEMA) to cover costs associated with distribution of critical supplies such as ventilators and PPE, medical staffing, National Guard support, vaccine distribution, and other needs.
Every single state had a public health emergency declaration in place, and dozens still do. FEMA covered $257 million in costs since March of 2020 that would otherwise have been covered by the Idaho state budget or local governments. That means without the emergency declaration, the State of Idaho would not be able to provide Idahoans with historic tax relief and unprecedented strategic investments to keep up with growth,"

Moriah Davis, *Two years since COVID-19 state of emergency in West Virginia declared*, WOWKTV.COM, (March 16, 2022), (April 22, 2022, 11:34 AM), https://www.wowktv.com/coronavirus-in-west-virginia/two-years-since-covid-19-state-of-emergency-in-west-virginia-declared/.

Office of the Governor, *West Virginia's Response to COVID-19, Governor Jim Justice, COVID-19 Actions and Executive Orders*, GOVERNOR.WV.GOV, (May 26, 2021 4:42 PM), https://governor.wv.gov/Pages/WV-COVID-19-actions-and-executive-orders.aspx, https://governor.wv.gov/Documents/2020%20Proclamations/State-of-Emergency-March-16-2020.pdf.

Ronald B. Brown, *Outcome Reporting Bias in COVID-19 Vaccine Trials*, MEDICINA (Feb. 26, 2021), https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996517/.

Former BlackRock Fund Manager Edward Dowd Reveals Wall Street Now Paying Attention to the 'Trust the Science' Fraud, DAILYCLOUT.IO, (April 18, 2022), (April 22, 2022, 11:29 AM), https://dailyclout.io/blackrocks-edward-dowd-reveals-wall-street-now-paying-attention-to-the-trust-the-science-fraud/.
"Blackrock's Edward Dowd reveals Wall Street is now paying attention to the "trust the science" fraud.
As Pfizer try to 'pump their stock' Hedge Fund guru Dowd, takes us inside what he calls the third great fraud in his lifetime, in this new bombshell interview with Dr. Naomi Wolf."

US Mortality, Death, Excess, Ranking, Map, Historical (since 2015), USMORTALITY.COM, (Retrieved April 22, 2022, 11:47 AM), https://www.usmortality.com/historical.

Julia Kollewe, *Pfizer accused of pandemic profiteering as profits double, Drugmaker makes $37bn in vaccine sales and predicts bumper year ahead from Covid jabs and pill*, THE GUARDIAN, (February 8, 2022), (April 22, 2022, 12:17 AM), https://www.theguardian.com/business/2022/feb/08/pfizer-covid-vaccine-pill-profits-sales.

Whitney Webb, *Operation Warp Speed Is Using A CIA-Linked Contractor To Keep Covid-19 Vaccine Contracts Secret*, THE LAST AMERICAN VAGABOND, (October 6, 2021), (June 5, 2021, 7:21 PM) https://www.thelastamericanvagabond.com/operation-warp-speed-is-using-a-cia-linked-contractor-to-keep-covid-19-vaccine-contracts-secret/.
'$6 billion in Covid-19 vaccine contracts awarded by Operation Warp Speed have been doled out by a secretive government contractor with deep ties to the CIA and DHS, escaping regulatory scrutiny and beyond the reach of FOIA requests.
Last Tuesday, while most Americans were distracted by the first US presidential debate, NPR quietly reported that the US government's Operation Warp Speed, a public-private partnership launched by the Trump administration to rapidly develop and distribute a Covid-19 vaccine, had taken the unusual step of awarding contracts to vaccine companies, not directly, but through a secretive defense contractor.
Though NPR named the defense contractor—South Carolina–based Advanced Technology International—they declined to explore the company's deep ties to the CIA, Department of Homeland Security, and the Department of Defense and how ATI is helping to lead those agencies' efforts to militarize health care and create a surveillance panopticon that not only monitors the world around us but our physiology as well.
The "secret" vaccine contracts awarded through ATI as part of Warp Speed total approximately $6 billion, accounting for the majority of Operation Warp Speed's $10 billion budget. Both Paul Mango, Health and Human Services' deputy chief of staff for policy, and Robert Kadlec, HHS assistant secretary for preparedness and response (ASPR), personally signed off on the contracts.
Operation Warp Speed, which officially involves the combined efforts of HHS and the military to deliver over 300 million Covid-19 vaccines to Americans by next January, is a highly

secretive program dominated by military personnel, most of whom have no experience in health care or vaccine production. The Trump administration has often compared Warp Speed to the Manhattan Project, which produced the atomic bomb.

Several very unsettling revelations about the true nature and scope of Warp Speed, including the out-sized role of ATI, began to emerge starting last Monday. Yet, most of this new information was not covered by US news outlets due to the media frenzy surrounding the first presidential debate and the subsequent news that President Trump and several other politicians and White House officials had tested positive for Covid-19.

NPR noted that the decision to use a nongovernment intermediary like ATI to issue the coronavirus vaccine contracts, as opposed to the government itself directly awarding those contracts, allows Operation Warp Speed to "bypass the regulatory oversight and transparency of traditional federal contracting mechanisms." This means that, among other things, the vaccine contracts awarded under Operation Warp Speed are unlikely to be publicly released in the near future, if ever.

The report from NPR also noted that the Congressional Research Service reported just last year that using such intermediaries to award contracts can result in "significant risks, including potentially diminished oversight and exemption from laws and regulations designed to protect government and taxpayer interests." Proponents of this unorthodox way of issuing contracts, known as "other transaction agreements" (OTAs), often argue that utilizing this alternative method for awarding contracts significantly hastens the process. However, the Congressional Research Service also noted that the Department of Defense, which has been increasingly relying on OTAs in recent years, has never tracked the information necessary to determine if OTAs are actually faster than traditional contracting methods. This suggests that claims regarding the alleged "speed advantage" of OTAs are based on assumptions rather than data-based evidence.

Johnson & Johnson, Novavax, Pfizer, and Sanofi are among the companies that have received these covert vaccine contracts through the OTA authorized by Operation Warp Speed and managed by ATI. Many of these companies, particularly Johnson & Johnson, have been involved in scandals related to selling and marketing products they knew to be unsafe to the public. This makes the lack of oversight and their exemption from federal regulations (including safety regulations) an issue of concern regarding their participation in Warp Speed. This concern is further compounded by the fact that, on September 21, HHS Secretary Alex Azar told FOX Business that all Operation Warp Speed vaccine manufacturers would be exempt from liability for any damages their vaccines may cause and that those who administer their vaccines would also not be liable for damages. "Under the PREP Act, which is a provision in Congress, any treatment or vaccine for purposes of a national emergency pandemic like this actually comes with liability protection. Both the product as well as those who administer it or provide it," Azar stated during the televised interview. The PREP Act that Azar referenced was originally signed into law in 2005 but was updated this past April, a few weeks before Operation Warp Speed was announced, so that vaccine and therapeutic manufacturers "cannot be sued for money damages in court" over injuries caused by medical countermeasures for Covid-19.'

Department of Justice Office of Public Affairs, *Justice Department Announces Largest Health Care Fraud Settlement in Its History, Pfizer to Pay $2.3 Billion for Fraudulent Marketing*,

(September 2, 2009), (April 22, 2022, 11:57 AM), https://www.justice.gov/opa/pr/justice-department-announces-largest-health-care-fraud-settlement-its-history.

Kelly Sadler, *Follow the money: Big Pharma, Dr. Fauci and the death of hydroxychloroquine*, Opinion, THE WASHINGTON TIMES, (June 9, 2021), (August 3, 2021, 7:38 PM), https://www.washingtontimes.com/news/2021/jun/9/follow-the-money-big-pharma-dr-fauci-and-the-death/.

'The $2.45 million Gilead spent in the first quarter of 2020 lobbying the federal government was well spent.

To better understand how using hydroxychloroquine (HCQ) to treat COVID-19 patients last year became a scientific quagmire, it's always best to follow the money.

HCQ is cheap (costing under $10 for the course of a COVID-19 treatment), well-understood by physicians having been prescribed for more than 80 years, and can be taken orally. Yet, Dr. Anthony Fauci and others at the National Health Institute of Allergy and Infectious Diseases preferred remdesivir, a proprietary, intravenous drug manufactured by Gilead Sciences, costing about $3,500 per treatment, with unknown side effects. And as to not make Big Pharma mad — and possibly threaten invites to cocktail parties, board seats and threaten grant monies — Dr. Fauci and his cohorts did everything possible to promote remdesivir and downplay HCQ, possibly costing millions of lives around the globe.

Although, many doctors around the world were finding success with HCQ, in February 2020 NIH started enrolling patients for a remdesivir COVID-19 trial, with Dr. Fauci overseeing its progress. He had the final say on all the press releases, and presumably was working closely with Gilead. On April 16 something funny happened with the trial — the endpoints of it were quietly changed and updated on the clinicaltrials.gov website. Instead of evaluating remdesivir's ability to prevent death from COVID-19, the study was redesigned to evaluate how fast a patient recovered from remdesivir.

It was an interesting change because a leaked World Health Organization study of remdesivir showed there was no statistically significant clinical benefits in using the drug on COVID-19 patients and that it had severe side effects. However, it did show some promise in reducing recovery time. When the news broke of this study to the public, on April 23, Gilead shares fell.

Drs. Dennis Bier at the Baylor College of Medicine and Arne Astrup, from the University of Copenhagen wrote in the BMJ Medical Trade Journal, NIH's decision to move its study's endpoints in the middle of the trial is generally frowned upon because the trial design is not drafted to focus on secondary endpoints, can produce data that's unreliable, and can "introduce bias into a trial and creates opportunities for manipulation."

Yet, on April 29, the NIH enthusiastically rolled out its results. During an appearance alongside former President Donald J. Trump in the Oval Office, Dr. Fauci said there was reason for optimism, the study achieved its primary goal, which was to improve the time to recovery, which was reduced by four days for patients on remdesivir. He failed to mention the study's endpoint was changed mid-way through the trial. Still, the media tour was started, with Dr. Fauci at the lead, praising remdesivir and simultaneously bashing HCQ for its lack of a similar clinical trial. Gilead's stock soared.

On May 1, the NIH's COVID-19 Treatment Guidelines panel members granted emergency use of remdesivir and stated HCQ could only be used in hospitals or in studies. Investigative journalist Sharyl Attkisson found 11 members of that panel had financial ties to Gilead. Two

were on Gilead's advisory board, others were paid consultants or received research support and honoraria. None of the members, however, had ties to HCQ, which is made by numerous generic manufacturers, and "is so cheap, analysts say even a spike in sales would not be a financial driver for the companies," Ms. Attkisson reported.

Ms. Attkisson also found one of the authors of a small Veterans Administration trial that claimed HCQ caused increased deaths received a $247,000 grant from Gilead in 2018.

On May 22, a fraudulent paper published by Lancet put the nail in HCQ's coffin, claiming to show HCQ was not effective and was dangerous. The lead author of the now-debunked and retracted study was Dr. Mandeep Mehra, a Harvard professor, who attended a conference co-sponsored by Gilead a month before to discuss COVID-19. Many have speculated whether Gilead ghostwrote the study, as Surgisphere the company that spearheaded the effort, had only a handful of recently hired staff that reportedly included a science fiction writer and an adult-content model.

Yet, the damage was done. On June 11, the NIH updated its COVID-19 guidelines recommending against the use of HCQ except for in clinical trials. Days later, on June 15, the Food and Drug Administration revoked emergency use of HCQ, with remdesivir being the only officially U.S. endorsed drug to treat COVID-19.

The $2.45 million Gilead spent in the first quarter of 2020 lobbying the federal government was well spent. Meanwhile, a new, not yet peer-reviewed study of HCQ released this month found it, taken with azithromycin, improved COVID-19 survival by nearly 200% in ventilated patients.

If only there were money in the drug. Imagine the lives that could've been saved.

• Kelly Sadler is commentary editor at The Washington Times.'

Office of the Governor, *COVID-19 UPDATE: Gov. Justice: "We're pushing the right buttons to keep this thing under control and away from us*," GOVERNOR.WV.GOV, (3/24/2020) (May 26, 2021, 5:30 PM), https://governor.wv.gov/News/press-releases/2020/Pages/COVID-19-UPDATE-Gov.-Justice-We%e2%80%99re-pushing-the-right-buttons-to-keep-this-thing-under-control-and-away-from-us.aspx.

Mylan Ramps Up U.S. Manufacturing of Hydroxychloroquine Sulfate Tablets to Meet Potential COVID-19 Patient Needs, INVESTOR.MYLAN.COM, (March 19, 2020), (April 22, 2022, 12:41 AM), https://investor.mylan.com/news-releases/news-release-details/mylan-ramps-us-manufacturing-hydroxychloroquine-sulfate-tablets.

"HERTFORDSHIRE, England and PITTSBURGH, March 19, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced its continued commitment to do its part in support of public health needs amidst the evolving COVID-19 pandemic. The company continues to focus its efforts on protecting our employees, producing critically needed medications, and turning our scientific and operational expertise towards identifying additional ways we may be able to assist in the massive prevention, diagnosis and treatment efforts needed to counter the spread of COVID-19.

For example, in the immediate term, Mylan has restarted production of hydroxychloroquine sulfate tablets at its West Virginia manufacturing facility in the U.S. to meet the potential for increased demand resulting from potential effectiveness of the product in treating COVID-19. Mylan's hydroxychloroquine sulfate tablets are approved by the U.S. Food and Drug

Administration (FDA) for the treatment of malaria, lupus erythematosus and rheumatoid arthritis. Although the product is not currently approved for use in the treatment of COVID-19, it is listed by the World Health Organization as a drug under investigation for efficacy against the coronavirus[1]. The company is also taking steps to initiate production of this product outside the U.S. in the coming weeks. We look forward to working with governments and health authorities globally to ensure patient access to this medicine as and where needed. Mylan expects to be in a position to begin supplying product by mid-April, and with the active pharmaceutical ingredient that we currently have available, will be able to ramp up manufacturing to provide 50 million tablets to potentially treat a total of more than 1.5 million patients. The potential use of this medicine for COVID-19 related treatment is pending additional FDA and other regulatory body guidance.
The growing global threat of COVID-19 requires a commitment by everyone involved in public health. Mylan takes its responsibility seriously and is committed to continuing to work with governments, partners and others to identify areas of need where our global R&D, regulatory and manufacturing expertise and capacity can be of service."

Jaimy Lee, *Mylan to restart production of hydroxychloroquine*, MARKETWATCH.COM, (March 19, 2020), (April 22, 2022, 1:02 AM), https://www.marketwatch.com/story/mylan-to-restart-production-of-hydroxychloroquine-2020-03-19?mod=article_inline.
"Shares of Mylan MYL, -2.10% were up 6% in trading on Thursday after the drugmaker restarted production of hydroxychloroquine-sulfate tablets, which are being considered as a possible treatment for people with COVID-19. Stephen Hahn, the commissioner of the Food and Drug Administration, said Thursday at a news conference with President Donald Trump that the regulator is evaluating granting expanded access to the drug, given the lack of proven treatment options for people sickened by the novel coronavirus. Mylan's hydroxychloroquine-sulfate tablets currently have FDA approval for malaria, lupus erythematosus and rheumatoid arthritis. The company said it may have a supply in place by mid-April, with the bandwidth to make 50 million tablets, which could treat about 1.5 million patients. Mylan's stock has dropped 25% year-to-date. The S&P 500 SPX, -1.48% is down 25%."

Douglas Soule, *How Mylan's Closure Of Its W.Va. Plant Was Years In The Makin*g, Mountain State Spotlight, WEST VIRGINIA PUBLIC BROADCASTING, (August 11, 2021) (aPRIL 22, 2022, 12:47AM), https://www.wvpublic.org/economy/2021-08-11/how-mylans-closure-of-its-wv-plant-was-years-in-the-making.

Pfizer Completes Transaction to Combine Its Upjohn Business with Mylan, PFIZER.COM, (November 16, 2020), (April 22, 2022, 12:50 AM), https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-transaction-combine-its-upjohn-business.
'NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) announced today that it has completed the transaction to spin off its Upjohn Business and combine it with Mylan N.V. to form Viatris Inc.
Pfizer Chairman and Chief Executive Officer Dr. Albert Bourla said, "We are proud to have completed the combination of Upjohn and Mylan to create Viatris and pleased to have delivered value to our shareholders through this transaction. I want to express my gratitude to

our Upjohn colleagues for their dedication in helping us achieve this milestone. Looking ahead at the new Pfizer, we believe our pipeline has never been stronger, and we are energized and inspired to continue developing breakthrough treatments and delivering innovative, life-changing medicines to patients around the world."
Under the terms of the transaction, which was structured as an all-stock Reverse Morris Trust, Upjohn Inc. was spun off to Pfizer stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan. The combined company was renamed "Viatris" in connection with the closing. In the distribution, Pfizer stockholders received approximately 0.124079 shares of Viatris common stock for every one share of Pfizer common stock held as of the close of business on the record date (which was November 13, 2020). In addition to the Viatris shares received in the distribution, Pfizer stockholders retained as of the closing the same number of shares of Pfizer common stock as they held immediately prior to the transaction. As of the closing of the combination, Pfizer stockholders owned approximately 57% of the outstanding shares of Viatris common stock, and Mylan shareholders owned approximately 43% of the outstanding shares of Viatris common stock, in each case on a fully diluted, as-converted and as-exercised basis.Viatris (Nasdaq: VTRS) will begin trading tomorrow, November 17, 2020.'

Douglas Soule, *With the Mylan plant closing, Morgantown wonders what's next*, MOUNTAINSTATESPOTLIGHT.ORG, (May 26th, 2021), (April 22, 2022, 11:13 AM), https://mountainstatespotlight.org/2021/05/26/mylan-plant-morgantown-wv-closure-job-loss/.

Jasmin Adous, *CISA grants Mylan critical infrastructure designation*, WDTV.COM, (July 31, 2021), (April 22, 2022, 1:10 AM), https://www.wdtv.com/2021/07/31/cybersecurity-infrastructure-security-agency-grants-mylan-critical-infrastructure-designation/.
'MORGANTOWN, W.Va (WDTV) - Just hours before the scheduled shutdown of the Mylan plant in Morgantown, 5 News got a response from the Cybersecurity and Infrastructure Security Agency.
The statement reads:
"We assure you that the critical infrastructure designation for critical manufacturing facilities, such as the Viatris facility in Morgantown, WV mentioned in your letter will remain in place."
We aren't certain on what this could mean, however Monongalia county Delegate Barbara Fleischauer sent 5 news a statement reading:
"I am very, very grateful to Congressman McKinley, Senator Manchin and Governor Justice for joining me in requesting critical infrastructure designation for the Mylan plant"
"This gives the employees and our entire community, hope."
Stick with 5 news on the air and online as we get more confirmation on what this could all mean for the plant.'

Office of the Governor, *Gov. Justice celebrates WVU's purchase of former Mylan plant in Morgantown*, GOVERNOR.WV.GOV, (March 31, 2022), (April 22, 2022, 12:55 AM), https://governor.wv.gov/News/press-releases/2022/Pages/Governor-Justice-celebrates-WVUs-purchase-of-former-Mylan-plant-in-Morgantown.aspx.
'CHARLESTON, WV – Gov. Jim Justice today celebrated West Virginia University's announcement that the WVU Innovation Corporation has officially taken ownership of the

former Mylan pharmaceutical manufacturing facility in Morgantown.
“There’s no doubt that when Viatris announced that they would be shutting down operations at the old Mylan plant, it was a real cannonball to the stomach for a lot of good people,” Gov. Justice said. “Every day, I kept thinking about the hardworking West Virginians in this community and how we had to do everything in our power to build a new future for this facility. I’m proud that’s exactly what happened. Now, we have an exciting new chapter to look forward to, where a facility that has already given us so much has the chance to continue producing medicines that are critical to our nation for years to come. When you have a pillar of our state as well known and as successful as WVU taking over such an important facility right in their backyard, you know the results are going to be tremendous.'

Sarah Baker, *Viatris Inc. (VTRS): These Shares Are Poised For Major Movemen*t, INVESTCHRONICLE.COM, (April 19, 2022), (April 22, 2022, 1:26 AM), https://investchronicle.com/2022/04/19/viatris-inc-vtrs-these-shares-are-poised-for-major-movement/.
'Let’s start up with the current stock price of Viatris Inc. (VTRS), which is $10.71 to be very precise. The Stock rose vividly during the last session to $10.98 after opening rate of $10.94 while the lowest price it went was recorded $10.64 before closing at $10.96.Recently in News on April 8, 2022, Viatris Inc. to Release First Quarter 2022 Financial Results on May 9, 2022. Viatris Inc. (NASDAQ: VTRS) plans to release its first quarter 2022 financial results on Monday, May 9, before the open of the U.S. financial markets. Chief Executive Officer Michael Goettler, President Rajiv Malik, and Chief Financial Officer Sanjeev Narula also will host a webcast at 8:30 a.m. EDT on May 9 to discuss the results. You can read further details here'

Stanton Mehr, *Viatris Sells Its Biosimilar Assets to Partner Biocon for $3.3 Billion*, BIOSIMILARSRR.COM, (March 3, 2022), (April 22, 2022, 1:30 AM), https://biosimilarsrr.com/2022/03/03/viatris-sells-its-biosimilar-assets-to-partner-biocon-for-3-3-billion/.
“Although Viatris seems to be cashing out its biosimilar portfolio, it is taking a 12% stake in Biocon Biologics as part of a $3.3 billion deal announced with the company February 28.”

Dave Bloom, *Viatris — Formerly Mylan — Agrees to $264 Million Settlement to Settle EpiPen Price Gouging Claims*, SNACKSAFELY.COM, (March 7, 2022), (April 22, 2022, 1:32 AM), https://snacksafely.com/2022/03/viatris-formerly-mylan-agrees-to-264-million-settlement-to-settle-epipen-price-gouging-claims/.
'Mylan leveraged the de facto monopoly status of EpiPen with insurers to raise the price from $100 to $600 over the years starting in 2008. In 2016, then Mylan CEO Heather Bresch was called before the House Committee on Oversight and Government Reform to defend the price hikes.
Epinephrine auto-injectors like EpiPen are life-saving devices that must be carried by individuals with allergies to food, insect venom, and environmental substances in case they suffer a severe, sometimes fatal reaction known as anaphylaxis.'

First Open Letter on the WHO’s Pandemic Treaty, WORLD COUNCIL FOR HEALTH,

(March 8, 2022), (April 22, 2022, 1:53 PM), https://worldcouncilforhealth.org/news/2022/03/pandemic-treaty/45591/.
The WHO agreement is unnecessary and threatens our sovereignty and inalienable rights
The WHO aims to confirm the pandemic agreement in the 77th World Health Assembly in 2024, but it could happen much sooner. World Council for Health will continue to raise awareness through campaigning against this undemocratic move.

Human Augmentation – The Dawn of a New Paradigm, GOV.UK, (Retrieved April 22, 2022, 1:56 PM), https://www.gov.uk/government/publications/human-augmentation-the-dawn-of-a-new-paradigm.
[Also see the menu on the right hand side of the page, outlining the technocrats' plans, including UN Agenda 2030.]